Prognostic Value of BNP in MCS - a 25 Year Follow up Study
Launched by RIGSHOSPITALET, DENMARK · May 3, 2020
Trial Information
Current as of July 05, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effect of a specific blood marker called BNP in patients with advanced heart failure who are receiving different types of treatment, including a durable mechanical assist device (a machine that helps the heart pump blood), heart transplants, or just medication. Researchers want to understand how BNP levels can help predict how these patients will do over time, with plans to follow them for 25 years after they join the study.
To be eligible, participants need to be at least 18 years old and must be referred to the Rigshospital in Denmark for advanced heart failure treatment. The trial is open to all genders. Once enrolled, participants will have regular check-ups to monitor their health and BNP levels. It’s important to know that if someone chooses not to give their consent to participate, they will not be able to join the study. This research could provide valuable insights into managing heart failure and improving patient care in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients referred for evaluation for advanced HF treatment at the Rigshospital in Denmark
- • Age\>18 years
- Exclusion Criteria:
- • No consent
About Rigshospitalet, Denmark
Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials